Infusion reactions to monoclonal antibodies for solid tumors

immunologic mechanisms and risk factors.

Christine H. Chung, Bert H. O'Neil

Research output: Contribution to journalArticle

Abstract

The development of monoclonal antibodies targeting various receptors and ligands has been a significant advance in cancer therapy. These monoclonal antibodies are generally well tolerated. A subset of patients, however, experience infusion reactions with symptoms ranging from mild to life-threatening anaphylaxis. The underlying mechanisms of these reactions are not well characterized. In this review, current findings in clinical risk factor assessments and known mechanisms of these infusion reactions are discussed.

Original languageEnglish (US)
Pages (from-to)14-17
Number of pages4
JournalOncology
Volume23
Issue number2 Suppl 1
StatePublished - Feb 2009
Externally publishedYes

Fingerprint

Immunologic Factors
Monoclonal Antibodies
Anaphylaxis
Neoplasms
Ligands
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Infusion reactions to monoclonal antibodies for solid tumors : immunologic mechanisms and risk factors. / Chung, Christine H.; O'Neil, Bert H.

In: Oncology, Vol. 23, No. 2 Suppl 1, 02.2009, p. 14-17.

Research output: Contribution to journalArticle

Chung, Christine H. ; O'Neil, Bert H. / Infusion reactions to monoclonal antibodies for solid tumors : immunologic mechanisms and risk factors. In: Oncology. 2009 ; Vol. 23, No. 2 Suppl 1. pp. 14-17.
@article{2d7cf270cc574c94ab1a5b330ac4b667,
title = "Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors.",
abstract = "The development of monoclonal antibodies targeting various receptors and ligands has been a significant advance in cancer therapy. These monoclonal antibodies are generally well tolerated. A subset of patients, however, experience infusion reactions with symptoms ranging from mild to life-threatening anaphylaxis. The underlying mechanisms of these reactions are not well characterized. In this review, current findings in clinical risk factor assessments and known mechanisms of these infusion reactions are discussed.",
author = "Chung, {Christine H.} and O'Neil, {Bert H.}",
year = "2009",
month = "2",
language = "English (US)",
volume = "23",
pages = "14--17",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "2 Suppl 1",

}

TY - JOUR

T1 - Infusion reactions to monoclonal antibodies for solid tumors

T2 - immunologic mechanisms and risk factors.

AU - Chung, Christine H.

AU - O'Neil, Bert H.

PY - 2009/2

Y1 - 2009/2

N2 - The development of monoclonal antibodies targeting various receptors and ligands has been a significant advance in cancer therapy. These monoclonal antibodies are generally well tolerated. A subset of patients, however, experience infusion reactions with symptoms ranging from mild to life-threatening anaphylaxis. The underlying mechanisms of these reactions are not well characterized. In this review, current findings in clinical risk factor assessments and known mechanisms of these infusion reactions are discussed.

AB - The development of monoclonal antibodies targeting various receptors and ligands has been a significant advance in cancer therapy. These monoclonal antibodies are generally well tolerated. A subset of patients, however, experience infusion reactions with symptoms ranging from mild to life-threatening anaphylaxis. The underlying mechanisms of these reactions are not well characterized. In this review, current findings in clinical risk factor assessments and known mechanisms of these infusion reactions are discussed.

UR - http://www.scopus.com/inward/record.url?scp=65549168690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549168690&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 14

EP - 17

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 2 Suppl 1

ER -